公开(公告)号：US20100272750A1

公开(公告)日：2010-10-28

申请号：US12451743

申请日：2008-05-29

申请人： Marie-Ange Buyse ,  Denise Baker

发明人： Marie-Ange Buyse ,  Denise Baker

IPC分类号： A61K39/12 ,  C07K7/06 ,  C07H21/04 ,  C12N15/63 ,  C12N5/10 ,  A61P31/12

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/55566 ,  C07K2319/00 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2710/20051

摘要： The present invention is directed to HPV polyepitope construct and the use thereoffor the prevention and/or treatment of HPV infection.

摘要翻译： 本发明涉及HPV多表位构建体及其在HPV感染预防和/或治疗中的应用。

公开(公告)号：US20050129693A1

公开(公告)日：2005-06-16

申请号：US10985581

申请日：2004-11-10

申请人： Marie-Ange Buyse ,  Erwin Sablon

发明人： Marie-Ange Buyse ,  Erwin Sablon

IPC分类号： A61K38/00 ,  C07K14/00 ,  C07K16/00 ,  C07K16/24 ,  C07K16/46 ,  A61K39/395

CPC分类号： C07K16/00 ,  A61K38/00 ,  C07K16/249 ,  C07K16/468 ,  C07K2317/24 ,  C07K2319/00

摘要： The present invention concerns molecules which bind and neutralize the cytokine interferon-gamma. More specifically, the present invention relates to sheep-derived antibodies and engineered antibody constructs, such as humanized single-chain Fv fragments, chimeric antibodies, diabodies, triabodies, tetravalent antibodies, peptabodies and hexabodies which can be used to treat diseases wherein interferon-gamma activity is pathogenic. Examples of such diseases are: septic shock, cachexia, multiple sclerosis and psoriasis.

摘要翻译： 本发明涉及结合和中和细胞因子干扰素-γ的分子。 更具体地，本发明涉及可以用于治疗其中干扰素-γ的疾病的绵羊衍生的抗体和工程改造的抗体构建体，例如人源化单链Fv片段，嵌合抗体，双抗体，三抗体，四价抗体，肽抗体和六抗体 活动是致病的。 这些疾病的例子有：败血性休克，恶病质，多发性硬化和牛皮癣。

公开(公告)号：US06593079B1

公开(公告)日：2003-07-15

申请号：US09381009

申请日：2000-01-12

申请人： Frederic Donie ,  Elke Faatz ,  Barbara Upmeier ,  Eva Hoess ,  Marie-Ange Buyse ,  Eric Saman

发明人： Frederic Donie ,  Elke Faatz ,  Barbara Upmeier ,  Eva Hoess ,  Marie-Ange Buyse ,  Eric Saman

IPC分类号： C12Q106

CPC分类号： G01N33/56988 ,  C07K16/1054

摘要： The invention concerns a process for diagnosis of an HIV infection by means of an immunoassay using the specific detection of the p24 antigen of HIV1, HIV1-Sub0 and/or the p26 antigen of HIV2, at least one antibody against the env region of HIV1, HIV1-Sub0 and/or of HIV2 and at least one antibody against the pol and/or gag region of HIV1, HIV1-Sub0 and/or HIV2, reagent kits and test strips suitable for diagnostic procedure as well as monoclonal antibodies against p24 and their use.

摘要翻译： 本发明涉及通过免疫测定来诊断HIV感染的方法，其使用HIV2的HIV1，HIV1-Sub0和/或p26抗原的p24抗原的特异性检测，至少一种针对HIV1的env区域的抗体， HIV1-Sub0和/或HIV2的抗体和抗HIV1，HIV1-Sub0和/或HIV2的pol和/或gag区域的至少一种抗体，适用于诊断程序的试剂盒和测试条以及针对p24的单克隆抗体及其 使用。

公开(公告)号：US20170137520A1

公开(公告)日：2017-05-18

申请号：US15353867

申请日：2016-11-17

申请人： Juha Punnonen ,  Edward Bowman ,  Maribel Beaumont ,  Marie-Ange Buyse ,  Carlo Boutton ,  Bruno Dombrecht ,  Bjorn Victor ,  David Vlerick

发明人： Juha Punnonen ,  Edward Bowman ,  Maribel Beaumont ,  Marie-Ange Buyse ,  Carlo Boutton ,  Bruno Dombrecht ,  Bjorn Victor ,  David Vlerick

IPC分类号： C07K16/28 ,  A61K39/395

CPC分类号： C07K16/2818 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/18 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/403

摘要： The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

公开(公告)号：US09527925B2

公开(公告)日：2016-12-27

申请号：US13433359

申请日：2012-03-29

申请人： Andreas Gschwind ,  Rene Georg Ott ,  Joachim Boucneau ,  Marie-Ange Buyse ,  Erik Depla

发明人： Andreas Gschwind ,  Rene Georg Ott ,  Joachim Boucneau ,  Marie-Ange Buyse ,  Erik Depla

IPC分类号： C07K16/18 ,  C07K16/22 ,  C07K16/46

CPC分类号： C07K16/468 ,  C07K16/18 ,  C07K16/22 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.

摘要翻译： 结合VEGF和Ang2两者的双特异性结合分子，优选以免疫球蛋白单可变结构域（如VHH和结构域抗体）的形式，含有它们的药物组合物及其在治疗与VEGF-和/或Ang2介导的疾病相关的疾病中的用途 公开了对血管发生的作用。 此外，还描述了编码双特异性结合分子的核酸，宿主细胞及其制备方法。

公开(公告)号：US20130330346A1

公开(公告)日：2013-12-12

申请号：US13886530

申请日：2013-05-03

申请人： Zarin Brown ,  Michelle Bradley ,  Steven John Charlton ,  Gino Anselmus Van Heeke ,  Karen Cromie ,  Bruno Dombrecht ,  Soren Steffensen ,  Judith Baumeister ,  Marie-Paule Bouche ,  Carlo Boutton ,  Marie-Ange Buyse ,  Veerle Snoeck ,  Stephanie Staelens

发明人： Zarin Brown ,  Michelle Bradley ,  Steven John Charlton ,  Gino Anselmus Van Heeke ,  Karen Cromie ,  Bruno Dombrecht ,  Soren Steffensen ,  Judith Baumeister ,  Marie-Paule Bouche ,  Carlo Boutton ,  Marie-Ange Buyse ,  Veerle Snoeck ,  Stephanie Staelens

IPC分类号： C07K16/46

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K16/468 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31

摘要： The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

摘要翻译： 本发明涉及针对或特异性结合趋化因子受体CXCR2的多肽，特别涉及能够调节CXCR2信号转导的多肽。 本发明还涉及能够表达本发明多肽的核酸，载体和宿主细胞，包含多肽的药物组合物以及用于治疗涉及CXCR2异常功能的疾病的所述多肽和组合物的用途。

公开(公告)号：US20180009888A9

公开(公告)日：2018-01-11

申请号：US14128681

申请日：2012-06-25

申请人： Judith Baumeister ,  Marie-Paule Lucienne Armanda Bouche ,  Carlo Boutton ,  Marie-Ange Buyse ,  Veerle Snoeck ,  Stephanie Staelens ,  Bruno Dombrecht ,  Peter Schotte ,  Cedric Jozef Neotere Ververken ,  Gerald Beste ,  Guy Hermans ,  Soren Steffensen ,  Alexander Szyroki ,  Tinneke Denayer

发明人： Judith Baumeister ,  Marie-Paule Lucienne Armanda Bouche ,  Carlo Boutton ,  Marie-Ange Buyse ,  Veerle Snoeck ,  Stephanie Staelens ,  Bruno Dombrecht ,  Peter Schotte ,  Cedric Jozef Neotere Ververken ,  Gerald Beste ,  Guy Hermans ,  Soren Steffensen ,  Alexander Szyroki ,  Tinneke Denayer

IPC分类号： C07K16/28 ,  C07K16/42 ,  C07K16/00 ,  G01N33/68

CPC分类号： C07K16/28 ,  C07K16/00 ,  C07K16/4283 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2317/94 ,  C07K2319/30 ,  G01N33/6854

摘要： This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; —methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; —modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

公开(公告)号：US20170137521A1

公开(公告)日：2017-05-18

申请号：US15353886

申请日：2016-11-17

申请人： Juha Punnonen ,  Maribel Beaumont ,  Marie-Ange Buyse ,  Carlo Boutton ,  Bruno Dombrecht ,  Bjorn Victor

发明人： Juha Punnonen ,  Maribel Beaumont ,  Marie-Ange Buyse ,  Carlo Boutton ,  Bruno Dombrecht ,  Bjorn Victor

IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K14/765

CPC分类号： C07K16/2818 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K14/765 ,  C07K16/18 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/31

摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

公开(公告)号：US20170137517A1

公开(公告)日：2017-05-18

申请号：US15353919

申请日：2016-11-17

申请人： Edward Bowman ,  Maribel Beaumont ,  Marie-Ange Buyse ,  Carlo Boutton ,  Bruno Dombrecht ,  David Vlerick

发明人： Edward Bowman ,  Maribel Beaumont ,  Marie-Ange Buyse ,  Carlo Boutton ,  Bruno Dombrecht ,  David Vlerick

IPC分类号： C07K16/28 ,  A61K45/06 ,  C07K16/46 ,  A61K39/395

CPC分类号： C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/18 ,  C07K16/2818 ,  C07K16/468 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

公开(公告)号：US20070031377A1

公开(公告)日：2007-02-08

申请号：US10550175

申请日：2004-03-26

申请人： Stany Depraetere ,  Katrien Lorre ,  Marie-Ange Buyse

发明人： Stany Depraetere ,  Katrien Lorre ,  Marie-Ange Buyse

IPC分类号： A61K38/21 ,  A61K39/395 ,  C07K16/24

CPC分类号： A61K38/21 ,  A61K39/0005 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/6031 ,  C07K16/249

摘要： The present invention relates to preventing, or treating and/or reducing the severity or progression of Type 1 immune response-mediated inflammatory lung disease. More particularly, the present invention provides a method for preventing or treating chronic obstructive pulmonary disease (COPD), severe asthma, sarcoidosis, berylliosis or cystic fibrosis by neutralizing or reducing IFNγ bioactivity which can be achieved either by in vivo administration of IFNγ neutralizing molecules or by in vivo immunization with pharmaceutical compositions comprising immunogenic IFNγ proteins or IFNγ-derived (poly)peptides or their corresponding nucleic acid sequences.

摘要翻译： 本发明涉及预防，或治疗和/或降低1型免疫应答介导的炎症性肺病的严重性或进展。 更具体地，本发明提供了通过中和或降低IFNγ生物活性来预防或治疗慢性阻塞性肺疾病（COPD），严重哮喘，结节病，铍液或囊性纤维化的方法，其可以通过体内施用IFNγ中和分子或 通过用包含免疫原性IFNγ蛋白或IFNγ衍生（多）肽或其对应的核酸序列的药物组合物进行体内免疫。